vs
碧迪（BDX）与Pediatrix Medical Group, Inc.（MD）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Pediatrix Medical Group, Inc.的10.6倍（$5.3B vs $493.8M）。碧迪净利率更高（7.3% vs 6.8%，领先0.5%）。碧迪同比增速更快（-0.4% vs -1.7%）。过去两年碧迪的营收复合增速更高（2.0% vs -0.1%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Pediatrix Medical Group是美国领先的专科医疗服务提供商，核心业务覆盖母胎医学、新生儿科、儿科心脏病学等儿科亚专科领域，与美国各地医疗机构合作，为女性、新生儿及儿童提供循证专科医疗服务。
BDX vs MD — 直观对比
营收规模更大
BDX
是对方的10.6倍
$493.8M
营收增速更快
BDX
高出1.3%
-1.7%
净利率更高
BDX
高出0.5%
6.8%
两年增速更快
BDX
近两年复合增速
-0.1%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $493.8M |
| 净利润 | $382.0M | $33.7M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 9.9% |
| 净利率 | 7.3% | 6.8% |
| 营收同比 | -0.4% | -1.7% |
| 净利润同比 | 24.0% | 10.5% |
| 每股收益（稀释后） | $1.34 | $0.40 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXMD
| Q4 25 | $5.3B | $493.8M | ||
| Q3 25 | $5.9B | $492.9M | ||
| Q2 25 | $5.5B | $468.8M | ||
| Q1 25 | $5.3B | $458.4M | ||
| Q4 24 | $5.2B | $502.4M | ||
| Q3 24 | $5.4B | $511.2M | ||
| Q2 24 | $5.0B | $504.3M | ||
| Q1 24 | $5.0B | $495.1M |
净利润BDXMD
| Q4 25 | $382.0M | $33.7M | ||
| Q3 25 | $493.0M | $71.7M | ||
| Q2 25 | $574.0M | $39.3M | ||
| Q1 25 | $308.0M | $20.7M | ||
| Q4 24 | $303.0M | $30.5M | ||
| Q3 24 | $400.0M | $19.4M | ||
| Q2 24 | $487.0M | $-153.0M | ||
| Q1 24 | $537.0M | $4.0M |
毛利率BDXMD
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | — | ||
| Q2 25 | 47.8% | — | ||
| Q1 25 | 42.8% | — | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | — | ||
| Q2 24 | 46.2% | — | ||
| Q1 24 | 45.7% | — |
营业利润率BDXMD
| Q4 25 | 10.5% | 9.9% | ||
| Q3 25 | 11.8% | 13.8% | ||
| Q2 25 | 16.0% | 12.8% | ||
| Q1 25 | 10.4% | 7.0% | ||
| Q4 24 | 8.8% | 7.8% | ||
| Q3 24 | 11.4% | 6.6% | ||
| Q2 24 | 12.1% | -31.3% | ||
| Q1 24 | 14.5% | 3.2% |
净利率BDXMD
| Q4 25 | 7.3% | 6.8% | ||
| Q3 25 | 8.4% | 14.5% | ||
| Q2 25 | 10.4% | 8.4% | ||
| Q1 25 | 5.8% | 4.5% | ||
| Q4 24 | 5.9% | 6.1% | ||
| Q3 24 | 7.4% | 3.8% | ||
| Q2 24 | 9.8% | -30.3% | ||
| Q1 24 | 10.6% | 0.8% |
每股收益（稀释后）BDXMD
| Q4 25 | $1.34 | $0.40 | ||
| Q3 25 | $1.71 | $0.84 | ||
| Q2 25 | $2.00 | $0.46 | ||
| Q1 25 | $1.07 | $0.24 | ||
| Q4 24 | $1.04 | $0.37 | ||
| Q3 24 | $1.37 | $0.23 | ||
| Q2 24 | $1.68 | $-1.84 | ||
| Q1 24 | $1.85 | $0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $375.2M |
| 总债务越低越好 | — | $570.5M |
| 股东权益账面价值 | $25.3B | $865.9M |
| 总资产 | $54.8B | $2.2B |
| 负债/权益比越低杠杆越低 | — | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资BDXMD
| Q4 25 | $740.0M | $375.2M | ||
| Q3 25 | $641.0M | $340.1M | ||
| Q2 25 | $735.0M | $224.7M | ||
| Q1 25 | $667.0M | $99.0M | ||
| Q4 24 | $711.0M | $229.9M | ||
| Q3 24 | $1.7B | $103.8M | ||
| Q2 24 | $4.5B | $19.4M | ||
| Q1 24 | $2.3B | $8.0M |
总债务BDXMD
| Q4 25 | — | $570.5M | ||
| Q3 25 | — | $577.2M | ||
| Q2 25 | — | $583.9M | ||
| Q1 25 | — | $590.5M | ||
| Q4 24 | — | $597.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BDXMD
| Q4 25 | $25.3B | $865.9M | ||
| Q3 25 | $25.4B | $890.7M | ||
| Q2 25 | $25.5B | $833.8M | ||
| Q1 25 | $25.2B | $789.2M | ||
| Q4 24 | $25.2B | $764.9M | ||
| Q3 24 | $25.9B | $732.5M | ||
| Q2 24 | $25.9B | $706.5M | ||
| Q1 24 | $25.6B | $856.2M |
总资产BDXMD
| Q4 25 | $54.8B | $2.2B | ||
| Q3 25 | $55.3B | $2.2B | ||
| Q2 25 | $54.9B | $2.1B | ||
| Q1 25 | $54.5B | $2.0B | ||
| Q4 24 | $54.7B | $2.2B | ||
| Q3 24 | $57.3B | $2.1B | ||
| Q2 24 | $55.6B | $2.0B | ||
| Q1 24 | $54.2B | $2.2B |
负债/权益比BDXMD
| Q4 25 | — | 0.66× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | 0.70× | ||
| Q1 25 | — | 0.75× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $114.1M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | — |
| 自由现金流率自由现金流/营收 | 10.5% | — |
| 资本支出强度资本支出/营收 | 2.1% | — |
| 现金转化率经营现金流/净利润 | 1.72× | 3.39× |
| 过去12个月自由现金流最近4个季度 | $2.6B | — |
8季度趋势，按日历期对齐
经营现金流BDXMD
| Q4 25 | $657.0M | $114.1M | ||
| Q3 25 | $1.4B | $137.3M | ||
| Q2 25 | $1.2B | $137.2M | ||
| Q1 25 | $164.0M | $-117.5M | ||
| Q4 24 | $693.0M | $133.0M | ||
| Q3 24 | $1.2B | $91.8M | ||
| Q2 24 | $1.3B | $107.0M | ||
| Q1 24 | $514.0M | $-125.2M |
自由现金流BDXMD
| Q4 25 | $549.0M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $588.0M | — | ||
| Q3 24 | $882.0M | — | ||
| Q2 24 | $1.1B | — | ||
| Q1 24 | $380.0M | — |
自由现金流率BDXMD
| Q4 25 | 10.5% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 19.0% | — | ||
| Q1 25 | 0.7% | — | ||
| Q4 24 | 11.4% | — | ||
| Q3 24 | 16.2% | — | ||
| Q2 24 | 22.4% | — | ||
| Q1 24 | 7.5% | — |
资本支出强度BDXMD
| Q4 25 | 2.1% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 2.0% | — | ||
| Q3 24 | 5.4% | — | ||
| Q2 24 | 3.6% | — | ||
| Q1 24 | 2.7% | — |
现金转化率BDXMD
| Q4 25 | 1.72× | 3.39× | ||
| Q3 25 | 2.75× | 1.91× | ||
| Q2 25 | 2.12× | 3.49× | ||
| Q1 25 | 0.53× | -5.66× | ||
| Q4 24 | 2.29× | 4.36× | ||
| Q3 24 | 2.94× | 4.72× | ||
| Q2 24 | 2.66× | — | ||
| Q1 24 | 0.96× | -31.03× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
